On Oct 22, 2018, we, iGHP, had the honor to host Prof. Michael Abramoff, Founder and CEO of IDx; Mr. Fumio Ohue, Managing Executive Officer, General Manager of Eye Care Business Division, Topcon Corporation; and Mr. Ushio Usami, Country leader – Japan, Worldwide Public Sector, Amazon Web Services Japan K.K..
This seminar provided a talk by leading actors of the first-ever FDA approved AI automated diagnostic system, IDx-DR*, and its implications of for the future health care systems.
Prof. Abramoff presented the background of this significant breakthrough. He reflected back how he had focused on the device’s usability, quality and precision during the development phase, while also exploring ways to deliver the device to be used as a diagnostic tool at the primary care setting. This innovation comes from fundus camera developed by Topcon Corporation, which has been the leader in advanced eye care technology. Mr. Ohue described the business strategy and development for networking, while Mr. Ushio explained what cloud computing drives to health care and its future aspect. These collaboration brings social value and cost benefit in health care.
In the panel discussion, Prof. Miyata, as a moderator, asked the panelists whether the FDA’s authorization suggest that we are in the new era of autonomous AI diagnostic system without a doctor. The appeal of cost effectiveness, especially for preventative medicine, was stressed not only for the medical industry but also for the whole society. Prof Miyata also stressed that doctors are empowered rather than stripped of their powers with the assistance of such technology and that one of the reasons FDA may have approved this AI innovation is because this business model empowers family physicians.
97 participants in various fields attended and we explored the trend of advanced data science on next AI generation and innovation as value co-creation.
(*) IDx-DR analyzes image of the retina and detects signs of diabetic retinopathy. The machine also provides instant results of either a detection of signs of diabetic retinopathy and a recommendation for referral to an ophthalmologist or a lack of sign of diabetic retinopathy and recommendation for a follow-up in twelve months.